https://www.pharmacytimes.com/view/fda-approves-imetelstat-for-lower-risk-myelodysplastic-syndromes-with-transfusion-dependent-anemia
FDA Approves Imetelstat for Lower-Risk Myelodysplastic Syndromes With Transfusion-Dependent Anemia...
Oct 10, 2026 - Imetelstat (Rytelo; Geron Corp) is a first-in-class telomerase inhibitor.
transfusion dependent anemialower riskmyelodysplastic syndromesfdaapproves